Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. today reported third quarter 2020 financial results and corporate progress.

Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure presents positive clinical data with cavrotolimod at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced an upcoming poster presentation for cavrotolimod (AST-008), at the 35th Anniversary Annual Meeting of SITC.

Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.

Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust and Silicon Valley Bank.

Exicure Secures Debt Facility for Up to $25.0 Million

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual Key Opinion Leader (KOL) event to present preliminary Phase 1b efficacy and safety data.

Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced presentations at two upcoming conferences during the month of September.

Exicure to Present at Upcoming Conferences

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual KOL meeting on September 16th, 2020 to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod.

Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.

Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that David Giljohann, CEO, will present a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020.

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference 2020

Shares of Exicure Inc. XCUR, +3.46% gained 6% in premarket trading after it said that it will start enrolling patients in a Phase 2 trial for the biotech's experimental immuno-oncology drug.

Exicure shares rise on immuno-oncology trial

Allergan

Shares of the thinly traded micro-cap Exicure Inc (NASDAQ: XCUR) were advancing strongly Thursday in the wake of a collaboration agreement announced by the company with Allergan plc (NYSE: AGN).

Allergan, Exicure Strike Collaboration Agreement For Hair Loss Disorder Drugs

Shares of Exicure XCUR, -4.65% are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan AGN, -0.20% to develop treatments for hair loss disorders.

Exicures shares up on Allergan partnership

News for Exicure Inc Stock (XCUR)